Central Retinal Vein Occlusion Market

The central retinal vein occlusion market has been comprehensively analyzed in IMARC's new report titled "Central Retinal Vein Occlusion Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Central retinal vein occlusion (CRVO) develops when the major vein that drains blood from the retina becomes blocked, due to a blood clot. This obstruction disrupts normal blood flow, leading to a buildup of pressure in the retinal vessels and subsequent damage to the retina. Symptoms of CRVO can vary but often include sudden, painless vision loss or blurry vision, particularly in one eye. Some individuals suffering from the ailment may also experience distorted or distorted vision, as well as seeing floaters or dark spots in their visual field. Diagnosing CRVO typically involves a comprehensive eye examination by an ophthalmologist, including a dilated eye exam to assess the retina and its blood vessels. Optical coherence tomography (OCT) and fluorescein angiography are commonly used diagnostic tests to evaluate the extent of retinal damage and identify any areas of ischemia or swelling. Additionally, measuring intraocular pressure and assessing visual acuity help to determine the severity of the condition in patients.

The escalating cases of blood diseases, such as clotting disorders or abnormalities in blood cell composition that can elevate the risk of clot formation and vein occlusion, are primarily driving the central retinal vein occlusion market. In addition to this, the inflating utilization of efficacious medications like beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogs, aimed at managing symptoms and reducing further complications, is creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies, as these treatments help in fortifying muscles, refining coordination, and augmenting gross motor skills among individuals suffering from CRVO, is also bolstering the market growth. Apart from this, the rising usage of pulsed dye laser procedures, which specifically target abnormal blood vessels, resulting in their selective destruction and lightening of affected skin areas, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that entails the introduction of functional genetic material into cells to rectify or supplant mutated or dysfunctional genes underlying the disease pathology, is expected to drive the central retinal vein occlusion market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the central retinal vein occlusion market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for central retinal vein occlusion and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the central retinal vein occlusion market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the central retinal vein occlusion market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the central retinal vein occlusion market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current central retinal vein occlusion marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

• How has the central retinal vein occlusion market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the central retinal vein occlusion market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the central retinal vein occlusion market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of central retinal vein occlusion across the seven major markets?
• What is the number of prevalent cases (2018-2034) of central retinal vein occlusion by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of central retinal vein occlusion by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with central retinal vein occlusion across the seven major markets?
• What is the size of the central retinal vein occlusion patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of central retinal vein occlusion?
• What will be the growth rate of patients across the seven major markets?
   

Central Retinal Vein Occlusion: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for central retinal vein occlusion drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the central retinal vein occlusion market?
• What are the key regulatory events related to the central retinal vein occlusion market?
• What is the structure of clinical trial landscape by status related to the central retinal vein occlusion market?
• What is the structure of clinical trial landscape by phase related to the central retinal vein occlusion market?
• What is the structure of clinical trial landscape by route of administration related to the central retinal vein occlusion market?